FULGENT GENETICS INC (FLGT)
Health Care · NASDAQ
Fulgent Genetics develops and offers a broad menu of genetic testing services for molecular diagnostics, helping clinicians interpret patient DNA for disease prevention and treatment decisions.
What FULGENT GENETICS INC does
Fulgent Genetics is a clinical laboratory company that provides genetic testing and molecular diagnostic services. The company develops and commercializes laboratory-developed tests (LDTs) for a wide range of clinical applications, including oncology, inherited conditions, carrier screening, and pharmacogenomics. It operates its own CLIA-certified laboratory facilities and markets its tests directly to healthcare providers and patients, generating revenue through testing services, with key revenue drivers including the breadth of its test menu, customer demand patterns, and insurance reimbursement.
Themes: []
Fundamentals
- Price$20.88 as of 2026-07-09 close
- Market cap$592M as of 2026-07-10
- 1-year return+6.6% as of 2026-07-09 close
- Net margin-23.0% as of 2026-07-10
- Gross margin+38.7% as of 2026-07-10
- ROE-6.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+9.5% as of 2026-07-10
- Revenue CAGR (3y)-19.5% SEC XBRL
- Beta0.90 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.